» Articles » PMID: 32867363

Classical and Non-Classical Progesterone Signaling in Breast Cancers

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2020 Sep 2
PMID 32867363
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Much emphasis is placed on estrogen (E2) and estrogen receptor (ER) signaling as most research is focused on understanding E2 and ER's ability to enhance proliferative signals in breast cancers. Progesterone (P4) is important for normal mammary gland development, function and menstrual control. However, P4 and its receptors (PRs) in breast cancer etiology continue to be understudied and its role in breast cancer remains controversial. The Women's Health Initiative (WHI) clinical trial clearly demonstrated the importance of progestogens in breast cancer development. P4 has historically been associated with classical-signaling through nuclear receptors, however non-classical P4 signaling via membrane receptors has been described. Progestogens have the ability to bind to nuclear and membrane receptors and studies have demonstrated that both can promote breast cancer cell proliferation and breast tumor growth. In this review, we attempt to understand the classical and non-classical signaling role of P4 in breast cancers because both nuclear and membrane receptors could become viable therapeutic options for breast cancer patients.

Citing Articles

Non-Coding RNAs in Breast Cancer: Diagnostic and Therapeutic Implications.

Benacka R, Szaboova D, Gulasova Z, Hertelyova Z Int J Mol Sci. 2025; 26(1.

PMID: 39795985 PMC: 11719911. DOI: 10.3390/ijms26010127.


Novel Molecular Classification of Breast Cancer with PET Imaging.

Toan N Medicina (Kaunas). 2025; 60(12.

PMID: 39768978 PMC: 11678748. DOI: 10.3390/medicina60122099.


Insulin-like growth factor binding protein-6 modulates proliferative antagonism in response to progesterone in breast cancer.

Lariz F, Botero P, Shoffstall I, Houston K Front Endocrinol (Lausanne). 2024; 15:1450648.

PMID: 39698031 PMC: 11652171. DOI: 10.3389/fendo.2024.1450648.


Progesterone modulates cell growth via integrin αvβ3-dependent pathway in progesterone receptor-negative MDA-MB-231 cells.

Tsai C, Yang Y, Wang K, Chen Y, Chen Y, Yang J Heliyon. 2024; 10(13):e34006.

PMID: 39071644 PMC: 11283053. DOI: 10.1016/j.heliyon.2024.e34006.


Transcriptomic Profile of Breast Tissue of Premenopausal Women Following Treatment with Progesterone Receptor Modulator: Secondary Outcomes of a Randomized Controlled Trial.

Utjes D, Boggavarapu N, Rasul M, Koberg I, Zulliger A, Ponandai-Srinivasan S Int J Mol Sci. 2024; 25(14.

PMID: 39062832 PMC: 11277027. DOI: 10.3390/ijms25147590.


References
1.
Ruan X, Zhang Y, Mueck A, Willibald M, Seeger H, Fehm T . Increased expression of progesterone receptor membrane component 1 is associated with aggressive phenotype and poor prognosis in ER-positive and negative breast cancer. Menopause. 2016; 24(2):203-209. DOI: 10.1097/GME.0000000000000739. View

2.
Conneely O, Mulac-Jericevic B, DeMayo F, Lydon J, OMalley B . Reproductive functions of progesterone receptors. Recent Prog Horm Res. 2002; 57:339-55. DOI: 10.1210/rp.57.1.339. View

3.
Bashour N, Wray S . Progesterone directly and rapidly inhibits GnRH neuronal activity via progesterone receptor membrane component 1. Endocrinology. 2012; 153(9):4457-69. PMC: 3423625. DOI: 10.1210/en.2012-1122. View

4.
Mulac-Jericevic B, Lydon J, DeMayo F, Conneely O . Defective mammary gland morphogenesis in mice lacking the progesterone receptor B isoform. Proc Natl Acad Sci U S A. 2003; 100(17):9744-9. PMC: 187836. DOI: 10.1073/pnas.1732707100. View

5.
McGowan E, Clarke C . Effect of overexpression of progesterone receptor A on endogenous progestin-sensitive endpoints in breast cancer cells. Mol Endocrinol. 1999; 13(10):1657-71. DOI: 10.1210/mend.13.10.0356. View